/6190.T
6190.T Stock - PhoenixBio Co., Ltd.
Healthcare|BiotechnologyJPX
$473.00+0.85%
+$4.00 (+0.85%) • Dec 24
69
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.59
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $520.30
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for 6190.T
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$468.27 – $477.73
TARGET (TP)$543.95
STOP LOSS$435.16
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.25
52W High$809.00
52W Low$252.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $1.54B | $1.72B | $2.12B | $1.32B | $1.01B |
| Gross Profit | $1.11B | $1.20B | $1.56B | $727.79M | $588.14M |
| Gross Margin | 71.9% | 69.7% | 73.3% | 54.9% | 58.0% |
| Operating Income | $-135,168,000 | $11.06M | $508.45M | $-167,619,000 | $-276,889,000 |
| Net Income | $-445,650,000 | $26.38M | $493.33M | $-387,970,000 | $-238,002,000 |
| Net Margin | -28.9% | 1.5% | 23.2% | -29.3% | -23.5% |
| EPS | $-110.18 | $6.98 | $145.23 | $-117.50 | $-73.60 |
Company Overview
PhoenixBio Co., Ltd. provides contract study services for drug discovery and development primarily in Japan. The company uses PXB-mouse, a chimeric mouse with a humanized liver for use in drug development experiments; and in vitro studies using fresh human hepatocytes taken from PXB-cells. The chimeric mouse model with a humanized liver is used for in vivo studies in gene therapeutics, NASH/NAFLD drug development programs, anti-viral therapeutic tests, DMPK/toxicity studies, and custom transplantations. The company was founded in 2002 and is headquartered in Higashihiroshima, Japan.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
6190.TBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-1.69
Q4 2025
EPS Surprise History
Q4 23
No data
Q1 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
No data
Q2 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 14, 2025 | — | $-1.69 | — | — |
Q3 2025 | Aug 14, 2025 | — | — | — | — |
Q2 2025 | May 15, 2025 | — | $-74.46 | — | — |
Q1 2025 | Feb 12, 2025 | — | $-6.28 | — | — |
Q4 2024 | Nov 14, 2024 | — | $-36.52 | — | — |
Q3 2024 | Aug 13, 2024 | — | $5.75 | — | — |
Q2 2024 | May 15, 2024 | — | $2.98 | — | — |
Q1 2024 | Feb 14, 2024 | — | $-3.52 | — | — |
Q4 2023 | Nov 14, 2023 | — | $-3.92 | — | — |
Q2 2023 | Jun 30, 2023 | — | $11.59 | — | — |
Q1 2023 | Mar 31, 2023 | — | $19.31 | — | — |
Q4 2022 | Dec 31, 2022 | — | $6.53 | — | — |
Q4 2022 | Nov 14, 2022 | — | $76.39 | — | — |
Q3 2022 | Sep 30, 2022 | — | $50.80 | — | — |
Latest News
Loading news...
Frequently Asked Questions about 6190.T
What is 6190.T's current stock price?
PhoenixBio Co., Ltd. (6190.T) is currently trading at $473.00 per share. The stock has moved +0.85% today.
What is the analyst price target for 6190.T?
No analyst price targets are currently available for this stock.
What sector is PhoenixBio Co., Ltd. in?
PhoenixBio Co., Ltd. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the JPX exchange.
What is 6190.T's market cap?
PhoenixBio Co., Ltd. has a market capitalization of $1.93 billion, making it a small-cap company.
Does 6190.T pay dividends?
No, PhoenixBio Co., Ltd. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare Sector189A.T
D&M Co., Ltd.
$970.00
Mkt Cap: $2.2B
2342.T
Trans Genic Inc.
$254.00
Mkt Cap: $4.2B
2435.T
CEDAR.Co.,Ltd.
$211.00
Mkt Cap: $2.4B
4438.T
Welby Inc.
$282.00
Mkt Cap: $2.3B
4596.T
Kubota Pharmaceutical Holdings Co., Ltd.
$42.00
Mkt Cap: $2.5B
4884.T
Kringle Pharma, Inc.
$378.00
Mkt Cap: $2.6B
6063.T
Emergency Assistance Japan Co., Ltd.
$922.00
Mkt Cap: $2.3B
7083.T
AHC Group Inc.
$820.00
Mkt Cap: $1.7B
7090.T
Ligua Inc.
$895.00
Mkt Cap: $1.3B
9214.T
Recovery International Co.,Ltd.
$1450.00
Mkt Cap: $2.0B
Explore stocks similar to 6190.T for comparison